LifeMD, Inc. - Common Stock (LFMD)

LifeMD (NASDAQ:LFMD) reported second-quarter revenue of $47.3 million, within its prior guidance range, while posting an adjusted EBITDA loss of approximately $3.5 million as elevated customer acquisition costs and a lower introductory price for branded GLP-1 care pressured profitability. Chairman

LifeMD (LFMD) Q1 2026 Earnings Transcript

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a previous $12.00. This downgrade reflects growing concerns over the telehealth company's financial performance, operational efficiency, and competitive landscape. The immediate

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

LifeMD stock plunges after Q3 2025 earnings miss analyst estimates on both revenue and EPS, triggering a major sell-off.

As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Here's a look at the details from LifeMD's Q3 earnings report.

Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout.